High-amylose barley bread improves postprandial glycemia compared to regular barley and wheat bread in subjects with or without type 2 diabetes.

Background: Genetically modified (GMO) high-amylose barley lowers postprandial glucose. Since certain EU countries do not allow GMO barley, we therefore assessed if high-amylose barley made from traditional breeding (Lean Baking Barley, LBB) lowers postprandial glucose compared to bread made from re...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Nutrition Vol. 79; no. 10; pp. 1000 - 1007
Autores principales: Bohl, Mette, Gregersen, Søren, Li, Zhihang, Blennow, Andreas, Hebelstrup, Kim H., Hermansen, Kjeld
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Springer Nature Oct2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188780096&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188780096
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09543007
        EUC
      jtl: European Journal of Clinical Nutrition
      issn: 09543007
      maglogo: N
    pubinfo:
      dt: Oct2025
      vid: 79
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        188780096
        186771414
        188780096
        188780096
        10.1038/s41430-025-01646-6
        188780096
      ppf: 1000
      ppct: 7
      formats:
      tig:
        atl: High-amylose barley bread improves postprandial glycemia compared to regular barley and wheat bread in subjects with or without type 2 diabetes.
      aug:
        au:
          Bohl, Mette
          Gregersen, Søren
          Li, Zhihang
          Blennow, Andreas
          Hebelstrup, Kim H.
          Hermansen, Kjeld
        affil: https://ror.org/040r8fr65 Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, 8200, Aarhus, Denmark
      sug:
        subj:
          Glucans Therapeutic Use
          Barley Therapeutic Use
          Postprandial Period Drug Effects
          Glycemic Index Drug Effects
          Wheat Therapeutic Use
          Bread Analysis
          Diabetes Mellitus, Type 2 Diet Therapy
          Food, Genetically Modified Therapeutic Use
          Satiation
          Incretins Metabolism
          Lipids Metabolism
          Glucagon Metabolism
          Taste
          Human
          Male
          Female
          Adolescence
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Randomized Controlled Trials
          Crossover Design
          Appetite
          Analysis of Variance
          Food Preferences
          Glycated Hemoglobin
          Statins
          Antihypertensive Agents
          Single-Blind Studies
          Random Assignment
          Insulin Blood
          Triglycerides Metabolism
          Glucagon-Like Peptides Metabolism
          Pretest-Posttest Design
          Data Analysis Software
          Enzyme-Linked Immunosorbent Assay
          Funding Source
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: Background: Genetically modified (GMO) high-amylose barley lowers postprandial glucose. Since certain EU countries do not allow GMO barley, we therefore assessed if high-amylose barley made from traditional breeding (Lean Baking Barley, LBB) lowers postprandial glucose compared to bread made from regular barley (RB) or wheat (WF) in individuals with or without type 2 diabetes (T2D). Methods: In a randomised crossover design, 38 participants (18 T2D and 20 non-T2D) consumed 160 g of bread made from 100% LBB, RB, or WF. Postprandial metabolic responses, appetite and bread perception were measured. A mixed model ANOVA was used for analysis. Results: LBB bread reduced 4 h postprandial glucose measured as incremental area under the curve (iAUC) by 41% and 39% vs. WF and RB bread in T2D and by 28% and 32% in non-T2D (all, P < 0.05). In T2D, LBB reduced postprandial insulin (iAUC) by 52% and 38% vs. WF and RB, and by 60% vs. WF in non-T2D (all, P < 0.05). Postprandial GIP (iAUC) was lower after LBB in both groups vs. RB and WF (P < 0.05). GLP-1 (iAUC) and FFA (tAUC) were lower after LBB vs. WF in non-T2D (P < 0.05), but not in T2D. Appetite scores were similar for all breads. Overall liking was higher for WF but did not differ between barley types. Conclusion: LBB breads reduce postprandial glucose and insulin compared to RB and WF bread in individuals irrespective of T2D. LBB may have potential as a functional food in prevention and management of T2D. ClinicalTrails.gov registration: NCT04702672.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N